Key Points
- Ra Capital Management, Hemab Therapeutics’ major shareholder, bought 3,802 shares on May 19 for about $94,936 at an average price of $24.97 per share.
- The firm has been actively increasing its stake, with several additional purchases in early May, including a much larger 2.675 million-share buy on May 4 for $48.15 million.
- Hemab Therapeutics shares were down 0.6% and opened at $26.30, while the company also reported a quarterly EPS of ($23.98).
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) major shareholder Ra Capital Management, L.P. acquired 996 shares of the firm's stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $24.94 per share, for a total transaction of $24,840.24. Following the completion of the purchase, the insider directly owned 6,376,968 shares of the company's stock, valued at approximately $159,041,581.92. The trade was a 0.02% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Tuesday, May 19th, Ra Capital Management, L.P. purchased 3,802 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $24.97 per share, for a total transaction of $94,935.94.
- On Tuesday, May 12th, Ra Capital Management, L.P. purchased 6,387 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $24.90 per share, for a total transaction of $159,036.30.
- On Monday, May 11th, Ra Capital Management, L.P. purchased 39,869 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $24.81 per share, for a total transaction of $989,149.89.
- On Friday, May 8th, Ra Capital Management, L.P. purchased 1,483 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $24.98 per share, for a total transaction of $37,045.34.
- On Thursday, May 7th, Ra Capital Management, L.P. purchased 9,906 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $24.46 per share, for a total transaction of $242,300.76.
- On Wednesday, May 6th, Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $24.60 per share, for a total transaction of $1,673,242.80.
- On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $24.63 per share, for a total transaction of $2,399,232.93.
- On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $18.00 per share, for a total transaction of $48,150,000.00.
Hemab Therapeutics Trading Down 0.6%
COAG opened at $26.30 on Friday. Hemab Therapeutics Holdings, Inc. has a one year low of $23.00 and a one year high of $36.61.
Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last released its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen upgraded shares of Hemab Therapeutics to a "hold" rating in a research report on Saturday, May 9th.
Read Our Latest Report on COAG
Hemab Therapeutics Company Profile
(
Get Free Report)
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company's research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.
Hemab's pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
